tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Okyo announces FDA authorized single-patient expanded IND for urcosimod
PremiumThe FlyOkyo announces FDA authorized single-patient expanded IND for urcosimod
12d ago
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential
Premium
Ratings
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential
1M ago
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase
Premium
Company Announcements
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase
1M ago
OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain
PremiumCompany AnnouncementsOKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain
2M ago
Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial
Premium
The Fly
Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial
2M ago
Okyo Pharma initiated with a Buy at B. Riley
Premium
The Fly
Okyo Pharma initiated with a Buy at B. Riley
2M ago
OKYO Pharma to Present Urcosimod at OIS XV
PremiumCompany AnnouncementsOKYO Pharma to Present Urcosimod at OIS XV
3M ago
OKYO Pharma to Present at BIO-Europe 2025 Highlighting Urcosimod Progress
Premium
Company Announcements
OKYO Pharma to Present at BIO-Europe 2025 Highlighting Urcosimod Progress
3M ago
OKYO Pharma’s Chairman Increases Stake with New Share Acquisition
Premium
Company Announcements
OKYO Pharma’s Chairman Increases Stake with New Share Acquisition
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100